For both induction and maintenance therapy, subcutaneous guselkumab significantly improves clinical outcomes in patients with ...
Tremfya could become the first IL-23 inhibitor with fully subcutaneous induction and maintenance options in the treatment of ...
YESINTEK is approved for Crohn's disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis, offering a ...
Biopharma doubles down on immunology and inflammation as companies target new pathways and seek to improve on current options ...
Manufacturing: As a result of FDA approval of RYONCIL in December 2024, the US$23.0 million provision against the value of inventory manufactured and expensed in prior periods was reversed and is now ...
The positive opinion is based on results from the pivotal Phase 3 SELECT-GCA trial that evaluated the efficacy and safety of upadacitinib ...
In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDI™ for all indications matching the reference ...
Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss operational highlights and financial results for the ...
ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s diseaseNew detailed data from the RELIEVE UCCD ...
Q2 2025 Earnings Conference Call February 26, 2025 5:00 PM ETCompany ParticipantsSilviu Itescu - Chief Executive ...
In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDI for all indications matching the reference ...
In addition, higher clinical remission rates were observed for both doses of duvakitug versus placebo in both advanced therapy ... indication (UC or CD) stratified by previous exposure to advanced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback